SCHEDULE: Vanguard Group Reports 0% Stake in Praxis Medicines

The Vanguard Group has filed an amended Schedule 13G, reporting zero beneficial ownership in Praxis Precision Medicines Inc. following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 2 to Schedule 13G regarding its beneficial ownership of Praxis Precision Medicines Inc. Common Stock.
• The filing indicates that The Vanguard Group now holds 0% beneficial ownership, representing 0 shares of Common Stock.
• This change is due to an internal realignment within The Vanguard Group, effective January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will report beneficial ownership separately, disaggregated from the parent entity.
• The subsidiaries and business divisions continue to pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event for Praxis Precision Medicines Inc. as it primarily reflects an administrative change in how The Vanguard Group reports its holdings, rather than a change in investment strategy or a divestment from the company by the broader Vanguard family of funds.

Negatives

• The Vanguard Group, as the parent entity, no longer reports beneficial ownership, which could be interpreted as a reduction in direct institutional visibility from the parent entity, though ownership may reside in its subsidiaries.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that Schedule 13G filings primarily reflect passive investment positions and changes in beneficial ownership. This specific filing by The Vanguard Group indicates an internal administrative restructuring rather than a strategic divestment from Praxis Precision Medicines Inc. It aligns with broader trends where large asset managers may disaggregate reporting across various funds or subsidiaries for regulatory compliance and internal management purposes, without necessarily altering the overall investment thesis of the broader firm.

Stakeholder Impact

• Shareholders of Praxis Precision Medicines Inc. may see a change in the reported institutional ownership by The Vanguard Group, though the underlying beneficial ownership may still reside within Vanguard's subsidiaries.
• Regulatory bodies will note the updated beneficial ownership reporting structure from The Vanguard Group.

Key Dates

Recommendation

The filing is an administrative update from The Vanguard Group regarding its internal reporting structure, not a reflection of Praxis Precision Medicines Inc.'s operational performance or future prospects. As such, it provides no new fundamental information to alter an existing investment thesis, warranting a 'hold' recommendation.

Keywords

Praxis Precision Medicines Inc, Vanguard Group, Schedule 13G, Beneficial Ownership, Institutional Ownership, SEC Filing, Common Stock, Investment Management, PRAX